[{"id":"30e6b0d2-9ae8-42e8-950a-d7ffc20b493b","acronym":"WIZARD201G","url":"https://clinicaltrials.gov/study/NCT03149003","created_at":"2021-06-30T14:53:13.951Z","updated_at":"2024-07-02T16:35:29.166Z","phase":"Phase 3","brief_title":"A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy","source_id_and_acronym":"NCT03149003 - WIZARD201G","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" MGMT • HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24:02 • HLA-A*24","tags":["MGMT • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24:02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 08/30/2021","study_completion_date":" 08/30/2021","last_update_posted":"2023-11-15"},{"id":"552ca11f-790a-4b84-becf-793c8ecee83b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02498665","created_at":"2021-01-18T12:02:59.664Z","updated_at":"2024-07-02T16:35:29.249Z","phase":"Phase 1","brief_title":"A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies","source_id_and_acronym":"NCT02498665","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" HLA-A • MUC16","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2023-11-14"},{"id":"95852f2d-c3f9-49a8-9023-dcdaab70f2d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02750891","created_at":"2021-01-18T13:28:43.111Z","updated_at":"2024-07-02T16:36:13.147Z","phase":"Phase 1/2","brief_title":"A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas","source_id_and_acronym":"NCT02750891","lead_sponsor":"Sumitomo Pharma Co., Ltd.","biomarkers":" PD-L1 • WT1","pipe":" | ","alterations":" PD-L1 expression • HLA-A*24","tags":["PD-L1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2022-04-12"},{"id":"d14351b0-6a7c-4a76-937b-a44735e97526","acronym":"","url":"https://clinicaltrials.gov/study/NCT02436252","created_at":"2021-02-01T11:52:50.145Z","updated_at":"2024-07-02T16:36:13.189Z","phase":"Phase 1/2","brief_title":"Study of DSP-7888 in Patients With Myelodysplastic Syndrome","source_id_and_acronym":"NCT02436252","lead_sponsor":"Sumitomo Pharma Co., Ltd.","biomarkers":" HLA-A • WT1","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2022-04-12"}]